Venous plasma bupivacaine concentrations were measured in patients undergoing resection and reconstruction surgery for intra-oial malignancy. Vth cranial nerve and cervical plexus blocks were performed using 0.5% bupivacaine. Total dosage was higher than recommended by U.K. manufacturers. Mean peak venous plasma concentrations were higher than previously recorded. A «ignifirant difference was found in the peak concentrations when adrenaline was included. The irignifiranrr of these results in relation to systemic toxicity and recommended dosage is discussed.
Regional nerve blockade with a local anaesthetic agent requires the use of varying concentrations and volumes of the drug depending on the site of nerve blockade, the area requiring anaesthesia, and the necessity for motor as well as sensory blockade.
Bupivacaine is being used increasingly to produce regional nerve blockade, the prolonged duration of action providing analgesia both during and after operation. U.K. manufacturers recommend a maximum dosage in any 4-h period of 2mgkg~1, thus allowing 25-30ml of 0.5% solution for a 65-70-kg adult. However, strict adherence to these guidelines can lead to incomplete blockade. Charlton (1981) reported a 25% failure to block the lateral femoral cutaneous nerve when using 30 ml of solution to perform the perivascular technique of lumbar plexus anaesthesia.
The alternative of a more dilute solution is associated with a slower onset of action and incomplete motor blockade (Moore et al., 1970 (Moore et al., ,1971 and so, to ensure rapid onset of sensory anaesthesia and complete motor blockade, these authors recommended the use of 0.5% bupivacaine. As a necessary consequence of this, Moore and colleagues (1976, 1978) have used much larger amounts of the drug than the U.K. recommendation permits. However, in a series of 11080 regional nerve blocks they found only 15 patients with systemic toxic effects resulting from either accidental intravascular injection or absorption.
In a recent study of various techniques of axillary nerve blockade Touminen, Rosenberg and Kalso (1983) administered bupivacaine in excess of 3mgkg"' to a total dose as high as 600 mg. The highest individual plasma concentration was 3.3 ng ml" 1 with a mean peak concentration less than 2 ngml" 1 with any technique. No toxic side-effects were observed either for the duration of the block or in the recovery period.
The principal factor which determines toxicity is probably the particular regional block undertaken, and relates to the vascularity of the area, and the possibility of intravascular injection. Moore and colleagues (1976) considered that the techniques which they used minimized the risk of bolus i.v. injections; neither were the injections made into an area of high vascularity. This probably accounts for their finding that, in a series of 30 patients receiving bupivacaine 300-400 mg, only one patient achieved the plasma concentration of 4 fig ml" 1 which has been reported previously as likely to produce serious toxic effects and convulsions (Jorfeldt et al., 1968) . This patient showed no evidence of toxicity.
The present study was designed to determine the plasma concentrations of bupivacaine following blockade of the Vth cranial nerve and the cervical plexus to produce analgesia for resection and reconstruction of intra-oral carcinoma. The injections were made into areas of high vascularity with a fixed needle position and theoretically there was a higher risk of bolus intravascular injection. Total bupivacaine dosage was determined by the concentration (0.375% minimum) and volume considered necessary to ensure successful blockade.
PATIENTS AND METHODS
All patients were informed of the nature of the investigation during the routine pre-operative visit, and consent obtained for withdrawal of venous samples for bupivacaine estimation. Premedication was with pethidine and promethazine i.m. in appropriate dosage at least 90 min before surgery.
Anaesthesia was induced with a mixture of morphine (mean±SD) 9.1±2.4mg and droperidol 8.4±2.3mg followed by 2.5% thiopentone solution 22 5 ± 46.8 mg or the inhalation of 60% nitrous oxide and halothane in oxygen (or thiopentone and inhalation) until the depth of anaesthesia permitted tracheal intubation. ECG and heart rate were displayed continuously on an oscilloscope (Rigel) and arterial pressure was monitored intermittently using either an arteriosonde (Roche) or Dinamap (Critikon). Two 16-gauge Teflon catheters were inserted to superficial veins: one for the infusion of fluid, while the other, flushed with heparinized saline, permitted the withdrawal of venous blood for measurement of bupivacaine.
Regional nerve blockade was performed using the techniques described by Moore (1975) , the specific blocks required being determined following consultation with the surgeon as to the extent of the resection, and the proposed method of reconstruction. Most frequently, bilateral Vth cranial nerve and cervical plexus blocks were required (table I). Frequent aspiration was used during the procedure to minimize the risk of accidental i.v. injection.
Anaesthesia was maintained (table II) with 60% nitrous oxide and 0.4 ±0.1% halothane in oxygen using the Bain system with a fresh gas flow rate of 100 ml kg" 1 min"
1
. Incremental doses to a mean total of morphine 10.5±2.6mg and droperidol 10.6 + 2.8 mg were given, as indicated by alterations in the rate and depth of respiration, heart rate or arterial pressure, and in anticipation of surgical stimuli outside the blocked area, for example skin graft donor area or raising a distant flap (pectoralis major or delto pectoral).
Mean morphine consumption was 2.7 ±0.6 mg h"'. (It has since been found possible to decrease this requirement to less than 2 mg h" 1 by the use of a constant infusion technique.) Mean duration of surgery was 317 ± 49 min. 
Bupivacaine analysis
Plasma samples were analysed using an adaptation of the method of Zylber-Katz, Granit and Levy (1978) .
To each 2-ml aliquot of plasma was added 2 5 fig of internal standard solution (cyclizine hydrochloride; 11.4mgdl~' of hydrochloric acid 0.01 mol litre" 1 ), 0.5 ml sodium hydroxide lmol litre" 1 and diethyl ether 6 ml. The mixture was roll-mixed for 10 min, and then centrifuged at 3000 rev min" 1 for 5 min. The ether layer (5 ml) was removed by aspiration and transferred to a clean, tapered, glass-stoppered tube containing 0.5 ml hydrochloric acid 1 mol litre" 1 . After roll-mixing for 10 min and centrifugation (3000 rev min" 1 for 5 min), the ether layer was discarded, and the mixture made alkaline by addition of 0.25 ml sodium hydroxide 2.5 mol litre" 1 before extraction with chloroform 50/il and centrifugation (3000 rev min" 1 for 5 min). One to three microlitre of the organic phase was withdrawn and injected to the chromatographic column.
A Pye 104 gas chromatograph fitted with a flame ionization detector was used. Chromatographic conditions were as follows: The column was 2 m x 4 mm glass packed with 3% OV17 on 80/100 mesh chromosorb W.A.W. D.M.C.S. Q. Carrier gas was oxygen-free nitrogen at a flow-rate of 55 ml min" 1 . The column oven temperature was 25O°C with the injection port and detector temperatures set at 275°C and 300 °C, respectively.
A standard calibration curve of peak-height ratio of bupivacaine to internal standard v. bupivacaine concentration was constructed by analysis of spiked horse serum samples. These standards contained bupivacaine in the concentration range 0.25-5 fxgml" 1 , together with a constant amount of cyclizine hydrochloride (2 5 fig of internal standard solution added to each 2-ml sample).
The peak-height ratio of bupivacaine to internal standard was found for each of the test samples and the concentration of bupivacaine determined by reference to the calibration curve.
RESULTS
Plasma bupivacaine concentrations in nine patients are presented. One of these patients will be considered as an individual.
In five patients bupivacaine without adrenaline was used ( fig. 1) , one patient received bupivacaine with 1/200000 adrenaline while two patients received 1/400 000 adrenaline ( fig. 2) .
The mean total bupivacaine dose, 3.4 + 0.9 mgkg" 1 , exceeded the U.K. manufacturers' maximum recommended dose by 70% (table III) . Peak concentrations were obtained in four patients within 10 min of completion of the block, in one patient this was maintained for 30 min Peak concentrations (table IV) without adrenaline (4.95±0.96ngml~1) were significantly different (P<0.02) from those occurring with adrenalinecontaining solutions (3.56 ± 0.83 \ig ml" 1 ). No significant difference was detected between the solutions at 30 and 90 min.
In three patients (table III) the total dose of bupivacaine (mean 2.6mgkg" 1 ) approximated to the maximum recommended dose of 2.0-2.2 mg kg" 1 . Peak concentrations in these patients were 
DISCUSSION

Plasma bupivacaine concentrations
Both individual and mean peak venous plasma concentrations in this series were higher than those recorded by Moore and co-workers in 1976 and 1978 . Using 80ml of 0.5% bupivacaine with 1/320000 adrenaline for intercostal nerve block, venous plasma concentrations of 2.52 (range 1.4O-3.45)ngml-1 occurred 10-20min after injection. This compares with concentrations of 3.56 (range 3.05-4.52)ngml~' with adrenalinecontaining solutions and 4.95 (range 3.51-6.01) jig ml" 1 with adrenaline-free solutions in this series (volume of injection 43.8 ±6.5 ml; bupivacaine dosage 209.4 + 42.6 mg).
These peak concentrations appeared within 10-20 min of injection, regardless of the presence or absence of adrenaline. The higher concentrations reached in this series most probably reflect the difference in vascularity of the areas involved. The lower peak concentrations achieved with the adrenaline-containing solutions may unfortunately be counterbalanced by the increased risk of accidental intravascular injection. A compromise reached by the authors was to use the plain solutions for Vth nerve block, and adrenaline-containing solutions for the cervical plexus block.
Systemic toxicity
Jorfeldt and colleagues (1968), in a study carried out on conscious volunteers, infused bupivacaine i.v. to a total dose of 1.2 5 mg kg" 1 over a 20-min period. A mean concentration of 2.1 fig ml" 1 was reached without toxic effects. Assuming equipotency of doses used and by extrapolation from the concentrations of lignocaine which produced convulsions in dogs and man, they concluded that 4.0 fig ml" 1 was the bupivacaine concentration associated with convulsions in man. Mather, Long and Thomas (1971) advised that signs of toxicity would appear at Signal" 1 or greater. Moore, Balfour and Fitzgibbons (1979) , investigating the possible protective effect of diazepam premedication found that arterial plasma concentrations of 5.1-5.4 jig ml" 1 bupivacaine caused convulsions which ceased when the concentration decreased to 3.5-3.6/igml~'. Moore and co-workers (1978) found that peak arterial concentrations were •20-40% higher than simultaneously sampled venous concentrations. Six patients in the present series exhibited venous plasma concentrations in excess of 4.0jxgml" 1 at some point, two maintaining this concentration for 60 min. Both a£ these patients and one other achieved peak concentrations in excess of 5 fig ml" [ . If the factor of 20-40% is added to calculate arterial concentrations all patients would have had values in the range 4-5 jig ml"
1 . No evidence of toxicity was found in any patient, nor in a much larger series of elderly patients aged 7 5 years of age and older, many of poor physical status (A.S.A., III, IV) in whom similar volumes of bupivacaine were injected (personal observation).
Two possible explanations for this are suggested. First, that the induction of general anaesthesia conceals any toxic effects. Jorfeldt and colleagues (1968) commented that seizures occurring with lignocaine were easily controlled with a small dose of thiopentone. Second, that the high protein-binding capacity of bupivacaine results in a low free or unbound drug concentration. The protein-binding capacity of bupivacaine has been shown to be 90% at plasma concentrations up to Sjigml" 1 and there is general agreement that pharmacological activity is related to the free or unbound drug concentration (Tucker and Mather, 1976) . However, binding is reversible and the free concentration of the drug may not be constant. Low unbound drug concentration may also be offset by the intrinsic toxicity of the drug. Further study is required to determine the free plasma bupivacaine concentrations under similar clinical conditions.
Recommended dosage
The U.K. manufacturers' recommended maximum dose of bupivacaine 2mgkg" 1 in any 4-h period restricts the anaesthetist to a volume of 25-30ml of 0.5% solution in a 65-70-kg adult. If, as was the case in this series, there are patients weighing 50 kg or less, volume is restricted to 15 ml of 0.5% or 30 ml of 0.25% solution.
Previous authors Charlton (1981) and Moore and colleagues (1971) have commented on the failure rate following regional blockade using small volumes of solution, or more dilute concentrations of the anaesthetic agent. Moore and colleagues (1978) reported only 15 adverse effects in 11080 regional nerve blocks following doses of bupivacaine significantly larger than those recommended outside the U.S.A.
In our series, total drug dosage exceeded U.K. recommended values and this resulted in venous plasma bupivacaine concentrations higher than any previously recorded, excepting those in which the drug had been injected directly i.v. It is «ignifimnt that three patients in whom the drug dose was closest to the mnyimiim recommended dose exhibited equally high peak concentrations of bupivacaine.
Volumes and total dosage in all instances were considerably less than in series of intercostal nerve blockade (Moore et al., 1976) , or of axillary nerve blockade (Tuominen, Rosenberg and Ralso, 1983) . The presence of a large venous plexus in the ptcrygo-palatine fossa might explain the higher venous concentrations of bupivacaine following Vth nerve and cervical plexus blockade compared with figures previously published for intercostal and axillary nerve blockade. Anatomical features influencing rate of drug absorption mean that the site of injection of the local anaesthetic agent should be considered as important a determinant of the plasma concentration and possible toxicity as volume and total dosage. 
